Genentech’s Ocrevus heralds new chapter in MS treatment

The widely anticipated FDA approval of Genentech’s CD20-targeting antibody Ocrevus (ocrelizumab) for treating both relapsing and primary progressive forms of multiple sclerosis (MS), on March 28, marks the beginning of a new era in MS therapy…

Click here  to original publication.

Fonte: NATURE BIOTECHNOLOGY VOLUME 35 NUMBER 5 MAY 2017 393, 394